|Bid||373.81 x 800|
|Ask||389.09 x 800|
|Day's Range||379.00 - 386.90|
|52 Week Range||281.89 - 416.49|
|Beta (3Y Monthly)||1.59|
|PE Ratio (TTM)||24.41|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||428.76|
Christine Childrose’s human resources career has taken her from General Electric and Albany Molecular Research Inc. to Regeneron Pharmaceuticals, one of the region’s fastest-growing companies.
Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.” Their mean rating for Regeneron stock is 2.58, and their target price is $426.05, implying a 12.8% upside for the stock based on its December 10 closing price of $377.59.
In this year’s third quarter, Regeneron Pharmaceuticals’ (REGN) interest expenses rose YoY (year-over-year) to $7.49 million from $6.18 million, and its net other income rose YoY to $16.43 million from $11.86 million. Its income tax expenses fell YoY to $41.21 million from $177.29 million.
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
Moderna (NASDAQ:MRNA) went public on Dec. 7, raising $604 million on a market cap of $7.5 billion. The IPO met the goal, but a bad day on Wall Street sent the shares plummeting. It’s because Moderna represents the next wave in drug discovery. Like Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna is less a bet on particular drugs than on a method for finding them.
In the third quarter of this year, Regeneron Pharmaceuticals’ (REGN) selling, general, and administrative expenses rose YoY (year-over-year) to $369.23 million from $306.77 million, primarily due to a higher employee headcount. Meanwhile, its R&D (research and development) expenses rose YoY to $556.97 million from $529.75 million. It had R&D expenses of $2.03 billion and $2.23 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $2.07 billion in fiscal 2017.
Regeneron Pharmaceuticals (REGN) offers products treating ophthalmic, cardiovascular, neuromuscular, inflammatory, and infectious diseases. In this series, we’ll explore Regeneron’s financials and valuation, and analysts’ views on its stock.
In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017. Meanwhile, peers Amgen (AMGN), Biogen (BIIB), and Johnson & Johnson (JNJ) are expected to have revenue of $23.36 billion, $13.31 billion, and $81.35 billion, respectively, in fiscal 2018. Regeneron’s cash per share is $20.14, while Amgen’s, Biogen’s, and Johnson & Johnson’s cash per share is $45.17, $21.31, and $7.20, respectively.
Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren’t very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
The key driver behind the growth of biotech giant Regeneron Pharmaceuticals Inc. (REGN) may be facing competition, but not imminently. Right now, Regeneron's Eylea shares the top spot with Lucentis in the worldwide market for drugs to treat wet age-related macular degeneration (AMD). Lucentis is marketed by Novartis (NVS) outside North America and Roche (RHHBY) elsewhere in the world.
How Is Teva Pharmaceutical Positioned in 2018? On April 3, 2017, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Austedo for chorea associated with Huntington’s disease. According to Teva Pharmaceutical’s third-quarter earnings conference call, almost 40,000 people in the US suffer from Huntington’s disease.
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial ...
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today presented new data for REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), including promising clinical results in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) which are the two most common types of NHL. REGN1979 is a wholly-owned, investigational, full-length bispecific monoclonal antibody designed to trigger tumor killing by binding CD3 on immune system T-cells and CD20 on B-cell malignancies. Based on these data, Regeneron plans to initiate in 2019 a potentially registrational Phase 2 trial investigating REGN1979 in R/R FL.
I’ve been keeping an eye on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe Read More...